Author: gammy

Biologics License Application for Subcutaneous Formulation of “LEQEMBI(R)” (lecanemab) for the Treatment of Early Alzheimer’s Disease Accepted in China

TOKYO and CAMBRIDGE, Mass., Jan 6, 2026 – (JCN Newswire via SeaPRwire.com) – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the

More